daiichi sankyo co ltd
(4568:Tokyo Stock Exchange)
Mary Jane Helenek
Chief Executive Officer of Luitpold Pharmaceuticals Inc and President of Luitpold Pharmaceuticals Inc,Daiichi Sankyo Company, Limited
|Age||Total Calculated Compensation||This person is connected to 0 board members in 0 different organizations across 4 different industries.|
Ms. Mary Jane Helenek serves as the Chief Executive Officer and President at Luitpold Pharmaceuticals Inc., a subsidiary of Daiichi Sankyo Company Limited and PharmaForce, Inc.
3-5-1, Nihonbashi-honchoPhone: --
Tokyo, -- 103-8426
Board Members Memberships*There is no Board Members Memberships data available.
Education*There is no Education data available.
Annual Compensation*There is no Annual Compensation data available.
Stock Options*There is no Stock Options data available.
Total Compensation*There is no Total Compensation data available.
The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.
|Michael M. Morrissey Ph.D.||Chief Executive Officer, President and Director|
|Clive A. Meanwell M.D., Ph.D.||Chief Executive Officer and Director|
The Medicines Company
|Jeffrey M. Leiden M.D., Ph.D.||Chairman, Chief Executive Officer and President|
Vertex Pharmaceuticals Incorporated
|David D. Meek||Chief Executive Officer|
|Alexandre Merieux||Chief Executive Officer, Director and Member of Strategy Committee|
|€791.6K||Compensation as of Fiscal Year 2015.|
Sponsored Financial Commentaries
Only a company representative may request an update for the company profile. Documentation will be required.